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INTRODUCTION
Caffeine is the most widely used psychoactive drug in the 
world, being used habitually by more than 80% of adults world-
wide.1 Many different types of food and beverages contain caf-
feine, and caffeine consumption and withdrawal is known to 
cause many side effects. One of the most common side effects 
of caffeine consumption is sleep loss. The ability to stay awake 
longer is one of the major reasons for people to consume caffeine, 
whereas sleep loss is also a major reason for some not to consume 
caffeine.2 Caffeine can also help to alleviate negative mood ef-
fects brought on by lack of sleep.3 Negative effects of caffeine 
on sleep have been consistently found, including shortened total 
sleep time, prolonged sleep latency, and changes in the duration of 
light and deep sleep.4 In general, coffee consumption is lower in 
good sleepers than in poor sleepers and one study has shown that 
coffee consumed close to bedtime caused delayed onset of sleep, 
independent of total caffeine consumption throughout the day.5
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Caffeine is thought to be metabolized mainly in the liver 
by the cytochrome p450 CYP1A2, and metabolites are bro-
ken down further by the enzymes CYP2A6 and NAT2.6-8 Evi-
dence suggests that caffeine mediates its effects by acting as a 
competitive inhibitor at the adenosine receptors1 and the A2A 
receptor is hypothesized to be the main target for caffeine in the 
brain. Consistent with the mechanism of caffeine action on the 
A2A receptor, a polymorphism in the ADORA2A gene has been 
associated with caffeine consumption.9
The adenosine pathway is known to affect general sleep,10,11 
and caffeine’s antagonism of this pathway is thought to explain 
its effects on sleep. Hence, differential sensitivity to caffeine 
may explain individual differences in caffeine-related sleep 
loss. It has been previously shown in our sample that caffeine-
related sleep loss is heritable and there are genetic effects inde-
pendent of those on general insomnia,12 and a polymorphism in 
the ADORA2A gene is known to explain some of the variation 
in sleep loss after caffeine consumption.4 This finding is sup-
ported by mouse models, in which animals lacking A2A recep-
tors did not experience caffeine-induced wakefulness.13
So far, efforts to find genetic variants that contribute to varia-
tion in caffeine-related sleep effects have been confined to can-
didate gene studies and this approach has had some success,4 
whereas the only known linkage scan that was performed on 
the same sample used in the current study was less successful.12 
Genome-wide association studies (GWAS) allow testing of sev-
eral million common variants across the genome and require no 
prior hypothesis about potential association between a gene or 
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variant and the phenotype of interest. GWAS have been suc-
cessful in identifying variants that influence complex traits,14 
and in many cases, those variants have been part of biologic 
pathways that had never previously been implicated in those 
traits. Here, we carry out GWAS for caffeine-related sleep dis-
ruption in an attempt to identify additional variants that influ-
ence this trait, and to replicate the previous association finding 
in the ADORA2A gene. In addition, we carry out a gene-based 
test to identify genes that show evidence of association at mul-
tiple single nucleotide polymorphisms (SNPs). We combine the 
results of GWAS with gene expression data from cells that have 
been treated with caffeine, to test whether genes regulated by 
caffeine are more likely to show evidence of association than 
would be expected by chance. Finally, we use pathway analysis 
to test whether there is enrichment of association of genes in 
known biologic pathways.
METHODS
Participants
Between 1980 and 1982, a health and lifestyle questionnaire 
was administered by mail to 5,867 complete pairs of twins who 
had been registered with the Australian Twin Registry. Respons-
es were received from a total of 7,526 individuals (2,746 males 
and 4,780 females) and they had a mean age of 34.5 yr (standard 
deviation = 14.3). After removal of individuals who said that 
they do not drink tea or coffee, a total of 2,402 individuals from 
1,470 families provided both phenotype and genotype informa-
tion. Phenotypic and genotypic data collection was approved by 
the Queensland Institute of Medical Research Ethics Committee 
and informed consent was obtained from all participants.
Sleep Disturbance Measures
As part of the questionnaire, respondents were asked a num-
ber of questions about their sleep habits and how often they 
experience sleep disturbance. These included questions about 
the overall quality of sleep, variability in quality, depth of 
sleep, difficulty initiating sleep, anxious insomnia, depressed 
insomnia, and frequency of night waking. Principal compo-
nents analysis applied to this dataset previously showed that 
the sleep measures assessed in the questionnaire - sleep quality, 
variability of quality, initial insomnia, sleep latency, night-time 
waking, anxious insomnia, and depressed insomnia - appear to 
load strongly on a general sleep disturbance component that 
measures general insomnia.15 In the current analysis, principal 
components analysis was performed on the same variables to 
derive an overall score for insomnia for each individual. The 
analysis supported a single factor loading on these variables. 
Further information on the sleep disturbance measures in the 
questionnaire can be found in several studies.12,15,16
Participants were also asked the following question: 
If you were to drink COFFEE in the evening would it stop 
you from getting to sleep at night?
1) Always 2) Usually 3) Sometimes 4) Never
Given the low endorsement of the first two categories – Al-
ways (3.1%) and Usually (6.0%) – they were pooled with those 
who were sometimes affected. This divided the sample into 
those who were ever affected and those who were never af-
fected. After pooling, 678 individuals (32.1%) were classified 
as having ever suffered from caffeine-related sleep disturbance, 
whereas 1,432 individuals (67.8%) had never experienced sleep 
disturbance. The breakdown of the sample by zygosity is given 
in Table 1.
Genotyping
Genotype information was collected as part of a number of 
genotyping projects undertaken by the genetic epidemiology 
group at Queensland Institute of Medical Research. DNA sam-
ples were collected in accordance with standard protocols and 
submitted to different genotype centers using different single 
nucleotide polymorphism platforms (Illumina 317K, Illumina-
HumanCNV370- Quadv3, and Illumina Human 610-Quad, Illu-
mina Inc. San Diego, CA). A standard quality control procedure 
was used for all of the genotyping projects prior to imputation. 
A detailed description of the quality control steps and procedure 
for detection of ancestry outliers is given elsewhere.17 A set of 
274,604 SNPs that were common to all of the genotyping chips 
were used for imputation, which was performed using the Mar-
kov chain-based haplotyper (MACH) program.18 The imputa-
tion process uses information on the haplotype structure in the 
human genome from the HapMap project (Release22, Build36) 
to impute nongenotyped SNPs in the sample. The process that 
transfers pieces of DNA from one chromosome to another and 
thus shuffles the combinations, known as recombination, occurs 
nonrandomly throughout the genome. Therefore, segments of 
chromosomes are always transmitted as a unit and thus knowl-
edge of the genotype at one allele provides information on the 
genotypes at other alleles in the same segment of chromosome. 
The imputation process uses the information from genotyped 
SNPs to infer genotypes at nongenotyped SNPs. This process 
therefore allows for combining of genotype information from 
different SNP platforms as the missing SNPs on each platform 
can be imputed.
The imputed SNPs were screened further for mendelian 
errors, minor allele frequency, and missingness. Only SNPs 
with an imputation quality score (r2 – the squared correlation 
between the estimated genotype scores and true genotypes) 
greater than 0.3 were retained, which resulted in a total number 
of 2,380,486 SNPs.
Genome-wide Association Study
Two separate genome-wide association analyses were per-
formed. In both cases generalized estimating equations19 were 
used to test for association. This method allows inclusion of fam-
ily members in case-control analysis by adjusting the expected 
Table 1—Breakdown of the sample by zygosity
Monozygotic female pairs 425
Monozygotic male pairs 93
Dizygotic female pairs 94
Dizygotic male pairs 49
Opposite sex DZ pairs 96
Female twin siblings 31
Male twin siblings 5
Female nontwin singletons 402
Male nontwin singletons 158
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SNP variance due to familial relationships using a kinship ma-
trix. The generalized estimating equations method was imple-
mented in the freely available Generalized Disequilibrium Test 
software.20 In the first analysis, only age and sex were included as 
covariates. In the second analysis, the insomnia factor score was 
included as a covariate in addition to age and sex. The second test 
was performed to account for the variance in caffeine-induced in-
somnia caused by genetic variants that increase risk of insomnia 
independent of caffeine consumption. In both cases, an allelic 
test of association was used, which assumes an additive mode of 
action for each SNP and ignores dominance effects.
We used the threshold of 7.2 × 10-8 derived using simulations 
in a Caucasian population by Dudbridge and Gusnanto21 as the 
genome-wide significance level.
Post-GWAS analysis and annotation was carried out using 
the program WGAViewer.22 Because of the highly correlated 
nature of the results from imputed data, some regions will have 
many SNPs with similar P values. The clumping algorithm in 
PLINK23 was used to filter results and find the most significant 
independent signals. SNPs with pairwise r2 < 0.5 (a measure of 
linkage disequilibrium between SNPs) were considered to be 
independent signals.
Gene-Based Test 
To determine whether there are any genes that harbor an 
excess of SNPs with small P values, a gene-based test of as-
sociation was performed.24 The test uses the P values from the 
single SNP association analysis and computes an overall gene-
based test statistic by aggregating the individual SNP effects in 
each gene, accounting for the number of SNPs in each gene, 
and the correlation between them due to linkage disequilibrium 
(non-independence of SNPs). The association results from the 
analysis that included the insomnia factor score were used for 
computing the gene-based P values. A total of 17,681 genes 
were included in the gene-based analysis.
Gene Expression Analysis
Caffeine treatment was performed on three different cell 
types: (1) lymphoblastoid cell lines established from the blood 
of 24 females from hereditary non-BRCA1/2 breast cancer 
families recruited into the Kathleen Cuningham Foundation 
for Research into Breast Cancer (kConFab); (2) the colon can-
cer cell line, HT29; and (3) a cell line established from a breast 
to bone metastasis tumor. Experiments were performed in trip-
licate for each sample. Optimization experiments determined 
cell number and caffeine concentration for each cell type. 
Full details of the methods are provided in the study by Amin 
et al.25 Total RNA was extracted from both caffeine-treated 
and untreated control cells using the RNeasy RNA extraction 
kit (Qiagen, Hilden, Germany). A total of 156 samples (750 
ng complementary RNA per sample) were hybridized to Hu-
manHT-12 Expression BeadChips (Illumina Inc, San Diego, 
CA, USA) using all manufacturer’s reagents for washing, de-
tecting, and scanning as per the whole-genome gene expres-
sion direct hybridization assay protocol (Illumina Inc, San 
Diego, CA, USA).
The HumanHT-12 Expression BeadChips (Illumina Inc, San 
Diego, CA, USA) contains 48,803 probes that cover more than 
25,000 annotated genes. Expression data were collated and 
quality checked in the Illumina BeadStudio and then imported 
into GeneSpring V10.0 (Agilent Technologies, Santa Clara, 
CA, USA). Data were quantile normalized to the baseline of 
the median of all samples and then filtered using an Illumina 
detection score of 0.95 or greater in at least one sample. To 
identify differentially expressed genes between each caffeine-
treated sample to its own untreated control sample, a linear 
model was implemented using R and the LInear Mixed Models 
for MicroArray data (LIMMA)26 package. Data were adjusted 
for multiple testing with a false discovery rate of 5%. Two cri-
teria were used to select the set of relevant genes. First, a set 
of genes with a log odds > (B-statistic) was selected, followed 
by a hierarchical search of genes based on log-fold changes.
Gene lists were then imported into GeneSpring V10.0 (Agi-
lent Technologies) for data visualization and to determine over-
lapping genes between different cell types.
Enrichment Analysis
A rank-test was used to test for enrichment of genes whose 
expression level changed after treatment with caffeine. A to-
tal of 647 genes were differentially expressed in all three cell 
types and had at least one SNP typed for the gene-based test. To 
test whether this gene set was enriched in the gene-based test, 
an empirical distribution of mean ranks was generated by ran-
domly drawing 647 genes from the list in the gene-based test, 
and calculating the mean position on the list. This was repeated 
1 million times, and a P value was calculated by testing how 
many of the randomly drawn gene sets had a lower mean than 
the set of differentially expressed genes. In addition, the same 
test was carried out to compare whether genes that showed the 
greatest log-fold change either up or down in expression in the 
lymphoblastoid cell lines were enriched in the analysis.
Pathway Analysis
To test whether there was an enrichment of associations 
in genes that act in the same biologic pathway or genes that 
have strongly related functions, all genes with a P value less 
than 0.05 from the gene-based test were included in a pathway 
analysis in the Ingenuity Pathway analysis software (Ingenuity 
Systems Release 6.0, Ingenuity Systems Inc, Redwood City, 
CA, USA). The Ingenuity program collates information from 
published research articles regarding the structure, function, 
localization, and interactions of proteins and molecules and 
assigns them to functional and canonical pathways. This per-
mits testing for enrichment of a particular pathway that may 
be relevant to the trait of interest. The Fisher exact test is used 
initially to test whether a particular pathway is overrepresent-
ed, and the Benjamini-Hochberg method is used to correct the 
P values for multiple testing. A corrected P < 0.05 was consid-
ered to be significant.
RESULTS
The quantile-quantile plots of the observed versus expected 
–log10(P) from the two (noninsomnia adjusted and insomnia ad-
justed) association analyses are presented in Figure 1. No SNPs 
passed the genome-wide significance threshold (P < 7.2 × 10-8) 
and there was no evidence of population stratification as evi-
denced by the genomic control λ (the median χ2 association sta-
tistic divided by the median expected under the null hypothesis 
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of no association) being 0.99 for both analyses. Manhattan plots 
for both analyses are provided in Figure 2.
Table 2 shows the most significant SNPs for the associa-
tion analysis that was not adjusted for the general insomnia 
factor score. Many of the most significant associations are 
with SNPs that are found in intergenic regions some dis-
tance from the nearest gene, whereas others are found in 
or near genes that have not been well annotated and about 
whom little is known. The most significant SNP – rs6573232 
(P = 1.4 × 10-6) – is found in an intron of the PRIMA1 gene 
that codes for a proline-rich protein whose function is to or-
ganize acetylcholinesterase into tetramers and anchor it to the 
membrane of neurons.27 The gene has been shown to be up-
regulated during the neuronal differentiation process,28 and as 
such, may represent a good candidate to influence caffeine-
induced insomnia.
A set of intronic SNPs in the MTUS2 gene also shows evi-
dence of association (P = 4.0 × 10-6) with caffeine-induced 
insomnia (Table 2). The MTUS2 gene encodes the microtu-
bule-associated tumor suppressor candidate 2. The gene is also 
known as CAZIP and TIP150 and is known to be involved in 
development of the nervous system.29
Of the well-annotated genes, perhaps the most interesting 
is MTNR1B, which codes for one of two melatonin receptors. 
rs10830964, a SNP found downstream of this gene, shows 
strong evidence for association (P = 5.2 × 10-6, minor allele fre-
quency (MAF) = 0.12, odds ratio (OR) = 0.62 [0.50 – 0.77]).
Among the other genes that harbor SNPs showing evidence 
of association are NEDD4L, a gene that is known to regulate 
and interact with ion channels30,31 and that has previously been 
associated with hypertension,32 and P2RY2, a gene that codes 
for a G protein coupled receptor that is known to bind adenos-
ine and control Ca2+ influx in cells.
Figure 1—(A) Quantile-quantile (Q-Q) plot for analysis with age and sex 
as covariates only. (B) Q-Q plot for analysis with insomnia factor score 
included as a covariate.
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The most strongly associated SNPs from the analysis that 
included the general insomnia factor score as a covariate 
are shown in Table 3. The most significant SNP (rs521704, 
P = 1.9 × 10-6, MAF = 0.45, OR = 0.70 [0.62 – 0.78]) is an 
intergenic SNP, the nearest gene being GBP4, which codes 
for guanylate binding protein 4. GBP4 is part of a cluster of 
guanylate-binding genes on chromosome 1 that are induced by 
the immune system and hydrolyze guanosine triphosphate to 
guanosine diphosphate.33 Another SNP – rs12407812 - located 
nearby in GBP1, was also among the most significant variants, 
and the GBP genes ranked at or near the top of the gene-based 
test (Table 4). There is no evidence to suggest that these genes 
also act on adenosine, but adenosine and guanine have a similar 
structure. Like caffeine, both molecules are purines, and it is 
possible that proteins that bind to guanine may be inhibited by 
caffeine occupying the active site.
Other SNPs that rank among the most associated include 
SNPs located in introns of the LPHN2 and NEBL genes on chro-
mosomes 1 and 10, respectively. LPHN2 encodes a G protein-
coupled receptor that is expressed in brain that is the primary 
receptor for alpha-latrotoxin.34 This gene has been implicated 
in breast cancer.35 NEBL encodes a nebulin-like protein that is 
expressed primarily in cardiac tissue.
Testing of Previously Reported Association with rs5751876
A previous study identified rs5751876, a SNP in the adenos-
ine receptor gene ADORA2A, as being associated with indi-
vidual sensitivity to caffeine’s effects on sleep (P = 0.03).4 It 
was noted that those with C/C genotype were more likely to 
be sensitive to caffeine’s effects on sleep. The C allele is the 
major allele with a frequency of 59%, so those carrying the mi-
nor allele were less likely to be sensitive. Because this SNP 
was not included in the HapMap project and was also not in-
cluded on the genotyping chips used here, we could not directly 
try to replicate those results. However, based on data from the 
1000 Genomes Project (www.1000genomes.org), we identi-
fied a number of SNPs (rs5760423, rs5760425, rs3761422, 
MAF = 0.38) in the ADORA2A gene in perfect linkage disequi-
librium (LD) with the previously identified variant that were 
imputed in our dataset. We were able to replicate the previous 
Table 2—Annotated list of the most highly associated independent SNPs (P < 10-5) for the association analysis that was unadjusted for general insomnia
SNP CHR BP Location
Nearest 
gene
Distance 
to nearest 
gene in bp Allele Frequency OR
Lower 
95% CI
 Upper 
95% CI P Value
rs6575353 14 94205345 INTRONIC PRIMA1 0 G 0.10 0.68 0.53 0.89 1.40E-06
rs7628219 3 70626360 INTERGENIC RP11-430J3.1 -173914 T 0.18 1.61 1.33 1.96 1.70E-06
rs2065779 10 112877801 INTERGENIC RP11-479A21.1 12792 C 0.07 0.55 0.43 0.71 2.50E-06
rs12895096 14 94202390 INTRONIC PRIMA1 0 T 0.11 0.70 0.55 0.90 2.80E-06
rs11706236 3 55188273 INTERGENIC RP11-889D3.1 12665 G 0.14 0.63 0.51 0.76 3.60E-06
rs2388082 13 29961332 INTRONIC MTUS2 0 G 0.11 0.59 0.47 0.74 4.00E-06
rs10830964 11 92719681 DOWNSTREAM MTNR1B 3733 T 0.12 0.62 0.50 0.77 5.20E-06
rs158856 18 55910523 INTRONIC NEDD4L 0 T 0.34 0.71 0.62 0.83 7.20E-06
rs1791933 11 72894848 INTERGENIC P2RY2 -34496 T 0.02 0.27 0.15 0.48 7.80E-06
rs16905439 8 136989204 INTERGENIC AC105008.1 -234466 T 0.01 0.30 0.17 0.51 9.20E-06
rs2103117 1 15156736 INTRONIC RP1-21O18.1 0 A 0.11 0.62 0.51 0.77 9.90E-06
BP, base pair; CHR, Chromosome; CI, confidence interval; OR, odds ration; SNP, single nucleotide polymorphism.
Table 3—Annotated list of the most highly associated independent SNPs (P < 10-5) for the association analysis that included the general insomnia factor 
score as a covariate
SNP CHR BP Location Nearest gene
Distance 
to nearest 
gene in bp Allele Frequency OR
Lower 
95% CI
 Upper 
95% CI P Value
rs521704 1 89680554 INTERGENIC GBP4 -15939 A 0.45 0.70 0.62 0.78 1.90E-06
rs13172305 5 126011412 INTERGENIC RP11-772E11.1 -12070 A 0.14 1.76 1.39 2.24 3.40E-06
rs11878836 19 34441088 INTERGENIC AC008556.1 -22558 C 0.21 1.37 1.10 1.70 3.40E-06
rs561042 1 89652071 NON_
SYNONYMOUS_
CODING
GBP4 0 C 0.49 0.77 0.66 0.91 6.20E-06
rs12725617 1 82420338 INTRONIC LPHN2 0 T 0.19 0.74 0.61 0.90 7.30E-06
rs12407812 1 89517074 DOWNSTREAM GBP1 913 C 0.44 1.41 1.21 1.64 8.90E-06
rs9665295 10 21356592 INTRONIC NEBL 0 A 0.05 2.55 1.68 3.87 9.20E-06
rs2103117 1 15156736 INTRONIC RP1-21O18.1 0 A 0.11 0.61 0.49 0.76 9.80E-06
BP, base pair; CHR, Chromosome; CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
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findings, with the LD proxy SNPs having P = 0.019 with an OR 
of 0.62 (0.50 – 0.78) for the minor allele. From the OR it can be 
seen that the minor allele decreases the likelihood of experienc-
ing insomnia after coffee consumption, replicating the findings 
of Retey et al.4 A further SNP, rs4822498, that is in very strong 
LD (r2 = 0.99) with the previously associated SNP showed the 
strongest evidence for association of all the SNPs within 50 
kb either side of the ADORA2A gene (P = 0.0091, OR = 0.61 
[0.50 – 0.76]). This SNP is located in an open reading frame 
that is downstream of the ADORA2A gene on chromosome 22 
and is encoded on the opposite strand (C22orf45). A test for 
nonadditive effects (dominance and recessive) was performed 
for the most significant ADORA2A SNP (rs4822498) and for 
one of the SNPs in perfect LD with the previously identified 
SNP, but no significant effects were found. In addition, a test for 
interaction effects between rs4822498 and rs5760423 was per-
formed, but there was no evidence of an interaction (P = 0.98). 
Furthermore, an association scan of the region that conditioned 
upon the SNP rs4822498 failed to identify any other significant 
SNPs in the ADORA2A region.
Gene-Based Test
The most associated genes from the Versatile Gene-based As-
sociation Study (VEGAS) gene-based test are provided in Table 
4. As a comparison, the results for a number of candidate genes 
for caffeine-related insomnia are shown in gray. The ADORA2A 
gene ranked 527th on the list and had a P value of 0.028.
A total of 647 autosomal genes were found to be differentially 
expressed in all 3 cell types and also analyzed in the gene-based 
test. The highest ranking of these, at 43rd, is PDCD4 (P = 0.0025), 
a gene that is thought to play a role in programmed cell death. 
This gene is a tumor suppressor gene that is downregulated in a 
number of different forms of cancer.36,37 There was no evidence 
to suggest that the differentially expressed genes are more highly 
associated than would be expected by chance (P = 0.21).
Interestingly, the second highest-ranked gene in the gene-
based test, GBP1, was found to be differentially expressed in 
two of the cell types (lymphoblastoid cell lines and bone me-
tastasis), but not the other. After relaxing the constraints for 
inclusion in the rank-test to those genes that are differentially 
expressed in at least two genes (n = 2,038), there is still no 
evidence for enrichment of association (P = 0.16). A similar 
analysis of the most highly changed genes as measured by log-
fold change in expression levels also showed no evidence for 
enrichment. Table 5 lists genes ranked in the top 50 most sig-
nificant genes in the gene-based test and that are differentially 
expressed in at least two of the cell types. 
Pathway Analysis
A total of 628 genes had P < 0.05 from the gene-based test 
and could be assigned a function or pathway in the Ingenuity 
program. After accounting for multiple testing, no functional 
or canonical pathways showed evidence for enrichment. The 
most strongly significant biologic function was nucleic acid 
metabolism (P = 1.6 × 10-4). The nucleic acid metabolism func-
tion is further subdivided into more specific categories, many 
of which relate specifically to adenosine metabolism. The role 
of ADORA2A in mediating the signaling effects of adenosine 
were mentioned previously, but there are several other genes 
involved in adenosine metabolism that show evidence for asso-
ciation. The genes FXYD2 and EPHB6 are both involved in in-
Table 4—List of genes with P < 10-3 for gene-based association testa
Chr Gene
Number 
of SNPs P value Best SNP
Best SNP 
P value
1 ZNF691 71 4.40E-05 rs11210747 4.20E-05
1 GBP1 97 6.30E-05 rs10801703 8.60E-06
1 ERMAP 79 9.00E-05 rs11210747 4.20E-05
1 GBP7 100 0.000109 rs521704 1.90E-06
1 GBP2 78 0.000114 rs4233337 4.30E-06
1 GBP4 58 0.000125 rs521704 1.90E-06
9 C9orf97 81 0.00014 rs2031999 0.00013
7 FAM115C 14 0.000384 rs4636119 4.50E-05
7 CTAGE6 12 0.000414 rs4636119 4.50E-05
19 SYMPK 79 0.00042 rs12463359 0.00044
19 RSHL1 72 0.000444 rs12463359 0.00044
19 FOXA3 65 0.000498 rs4802279 0.00054
13 SLC46A3 101 0.000558 rs7998219 0.00026
1 GBP3 99 0.000806 rs10801703 8.60E-06
2 ACADL 37 0.000834 rs13009758 0.0014
14 CALM1 85 0.000934 rs2268433 0.00026
14 C14orf115 52 0.000969 rs10132336 0.00062
22 ADORA2A 77 0.0289 rs4822498 0.0091
15 CYP1A2 43 0.247 rs2071501 0.066
8 NAT2 167 0.617 rs4921917 0.01
11 DRD2 197 0.542 rs4483623 0.028
17 ADORA2B 65 0.088 rs1045599 0.03
1 ADORA3 177 0.551 rs2275796 0.04
1 ADORA1 187 0.821 rs12033162 0.04
aAs a comparison, P values for some selected candidate genes are shown 
in gray. Chr, Chromosome; SNPs, single nucleotide polymorphisms.
Table 5—List of genes ranked in the top 50 most significant in the gene-
based test and that were found to be differentially expressed in at least 
2 of the cell types
Chr Gene Gene-based test rank P value
1 GBP1 3 0.000063
9 C9orf97 8 0.00014
7 CTAGE6 11 0.000414
19 DMWD 21 0.00109
2 RRM2 24 0.001247
19 DMPK 25 0.001597
11 KCTD14 27 0.001647
16 POLR3K 37 0.002128
11 CASP4 40 0.00216
8 GINS4 41 0.00224
14 C14orf169 43 0.00232
16 C16ORF33 44 0.00235
10 PDCD4 48 0.0025
16 C16orf35 50 0.00279
Chr, Chromosome.
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creasing binding affinity of adenosine triphosphatase (ATPase) 
enzymes for ATP, thus increasing ATP metabolism, whereas 
ADK phosphorylates adenosine to adenosine monophosphate 
and ADAT1 is known to increase deamination of adenosine. 
Additionally, PAPSS1 is involved in the synthesis of phospho-
adenosine. Other genes in the nucleic acid such as RRM2 fall 
in to the nucleic acid metabolism category, but are not adenos-
ine-specific. Given the evidence to suggest the involvement of 
adenosine in both general sleep and in caffeine sensitivity, it 
is likely not a coincidence that the most significantly enriched 
pathway for association includes several genes involved in 
adenosine metabolism. Despite the lack of experiment-wise 
significance, variants in these genes are good candidates for as-
sociation with caffeine-attributed insomnia.
DISCUSSION
We have undertaken a genome-wide association study of 
caffeine-related sleep disturbance. Previous analysis of the da-
taset used here demonstrated that this trait is heritable and is 
influenced by genetic factors that are independent of those in-
fluencing general insomnia.12 The advantage of the GWAS ap-
proach is that it requires no prior hypothesis and in many cases, 
variants in genes that were never previously thought to be as-
sociated with a trait have been discovered, elucidating biologic 
pathways that have an effect on the phenotype of interest. Due 
to the large number of tests being carried out, stringent sig-
nificance levels are used to avoid false-positive associations, 
and as such, large sample sizes are required to detect variants 
with small effects on the phenotype. In this study, we have 
combined gene expression data from cells treated with caffeine 
with GWAS data in an attempt to gain more insight on caffeine 
metabolism in cells and differences in within-population ef-
fects of caffeine.
We have identified a number of genes that show evidence 
of association with caffeine-induced insomnia. The most sig-
nificant association when analyzing the caffeine-related in-
somnia without adjusting for general insomnia was rs6575353 
(P = 1.6 × 10-6) located in an intron of the PRIMA1 gene on 
chromosome 14. When general insomnia was included in the 
analysis, the most significant SNP was rs521704 (P = 1.9 × 10-6) 
located approximately 15 kb upstream of the GBP4 gene on 
chromosome 1. These associations did not reach genome-wide 
significance, but these SNPs can be targeted for replication in 
another sample.
Another potential target for replication is rs10830964, lo-
cated near the MTNR1B gene, which encodes a subunit of the 
melatonin receptor that is expressed primarily in the retina and 
brain. The SNP was among the highest ranked in the analy-
sis that excluded general insomnia (P = 5.2 × 10-6). Melatonin 
is a hormone produced by the pineal gland in the brain in re-
sponse to light and dark signals from the retina. It is an impor-
tant point of control of circadian rhythms and is at its highest 
concentration in the middle of the night and lowest during the 
day. Studies have shown that prolonged release of melatonin 
can help to cure insomnia in older people,38 and a drug called 
ramelteon, which acts as an agonist of the melatonin receptor 
B1, has been approved in clinical trials to treat insomnia (www.
fda.gov). Many other supplements that are designed to improve 
sleep quality contain slow-release melatonin. Polymorphisms 
in or near this gene are good candidates to contribute to suscep-
tibility to both caffeine-related and general insomnia. Common 
genetic variants in the MTNR1B gene have also been found to 
influence fasting glucose levels and type 2 diabetes in multiple 
populations.39,40 The SNP remained nominally significant after 
including the insomnia factor score as a covariate (P = 0.0003), 
indicating that its effect may act on caffeine-induced insomnia 
rather than on general insomnia.
In addition, we were able to replicate the previous findings 
of an association between a polymorphism in the ADORA2A 
gene rs5751876 and sleep disruption after caffeine consump-
tion. Although the SNP was not typed in our sample, we were 
able to use information from the 1000 Genomes Project to iden-
tify proxy SNPs in complete LD with the candidate SNP. This 
result is notable in that is one of very few associations from 
the candidate gene era in behavioral genetics to replicate in the 
GWAS era. It also highlights the difficulty in isolating the true 
causal variant in genetic association studies. The association 
signal identified in the initial study may in fact be due to cor-
relation with other variants (potentially variants not tested for 
in GWAS) in the same vicinity. But the ADORA2A gene should 
be targeted for future sequencing and functional studies in the 
context of caffeine consumption, caffeine-induced insomnia 
and general insomnia. These studies may help to identify the 
true causal variant in this region of the genome.
There are several factors that may have affected the power 
of our study. First, for the sleep disturbance measures, we have 
assigned each individual to one of two categories based on 
whether they had ever or never experienced sleep disturbance 
after drinking coffee. This was due to the very small numbers 
of people who always or usually experienced sleep disturbance 
after drinking coffee in the evening. So that the assumptions 
made when performing the association test are not violated, the 
trait was dichotomized. This leads to a loss of power as indi-
viduals who experience more severe caffeine-induced insomnia 
may be enriched for risk alleles relative to those who experience 
only minor insomnia and this variance is lost. In addition, we 
are relying on self-report data for all of the variables analyzed. 
These data may be influenced by perceptual biases. It is known 
that people with insomnia often underestimate how much sleep 
they receive. To this end, studies of sleep loss often use poly-
somnography or actigraphy to get an objective measure of sleep 
loss. These methods provide greater accuracy of measurement, 
but they are much more time-consuming and less conducive to 
the large sample sizes required for GWAS. It is worth noting, 
however, that the association in ADORA2A that was initially 
discovered in a sample that used polysomnography to assess 
caffeine-induced insomnia was replicated in our sample that re-
lied on self-report data on the same phenotype, which suggests 
that self-report data, while imperfect, is a somewhat reliable 
measure of the true phenotype and may be of particular use in 
large-scale genetic studies.
From the gene expression analysis, more than 600 genes that 
showed differential expression in each of three separate cell 
types were identified. All experiments were performed in trip-
licate, providing strong statistical support for the genes iden-
tified. On the basis that much of the genetic control of gene 
expression is by cis-acting elements, we tested to determine 
whether there was an enrichment of associations in SNPs in the 
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differentially expressed genes. There is no evidence that these 
genes are enriched for associations; however, we have identi-
fied several genes and SNPs therein that show strong evidence 
for association. These genes represent good targets for replica-
tion in another sample. In addition, several of the top genes for 
both phenotypes show differential expression in at least two of 
the cell types, and so are good candidate genes for playing a 
role in caffeine sensitivity.
Analysis of gene expression data can give insight into the ge-
netic underpinnings of phenotypic variation and, in the case of 
caffeine, the downstream changes in expression that occur are 
not well understood. The data analyzed here help to elucidate 
some of those changes. Understanding these changes in gene 
expression will aid in understanding the biologic pathways un-
derlying sleep regulation in humans, and will have implications 
for insomnia and how it can be treated. The gene expression 
results should be interpreted with caution for reasons outlined 
elsewhere.25 However, the results from gene expression experi-
ments can aid in the interpretation of results from GWAS stud-
ies by providing more evidence for a role for specific genes that 
show evidence of association with the phenotype of interest. 
This is particularly useful given that in many cases, the sample 
sizes required to detect genome-wide significant effects are not 
achievable.
Pathway analysis represents another method of analyzing 
GWAS data and can offer insights into the genetic architecture 
of phenotypes. Given that most of the variants found in GWAS 
so far have had a small effect on the phenotype, it is likely 
many genes of small effect account for most of the heritability 
of complex traits. Many of these variants could potentially be 
found in the same pathway, with minor disruptions in several 
points in a pathway adding up to a substantial contribution to 
the observed variance. One of the most significantly enriched 
pathways in the association analysis was nucleic acid metabo-
lism, with many of the genes specifically involved in adenos-
ine metabolism. This is not inconsistent with the hypothesized 
mode of action of caffeine in the brain, and the general path-
ways involved in sleep.
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